BioDelivery Sciences International Inc.

BioDelivery Sciences International is a pharmaceutical company with a focus in the areas of pain management and addiction medicine. The company has built a portfolio of products utilizing its proprietary BioErodible MucoAdhesive (BEMA?) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The company's U.S. FDA approved products, BELBUCA? (buprenorphine) buccal film for chronic pain and BUNAVAIL? (buprenorphine and naloxone) buccal film for the treatment of opioid dependence, utilize the company's BEMA? technology. The company's other approved product, ONSOLIS? (fentanyl buccal soluble film), is indicated for the treatment of breakthrough pain.
  • TickerBDSI
  • ISINUS09060J1060
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

1 director sold

A director at Biodelivery Sciences International Inc sold 90,706 shares at 4.390USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rule...

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

ValuEngine Rating and Forecast Report for BDSI

MarketLine Department

Assertio Therapeutics, Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Assertio Therapeutics, Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Assertio Therapeutics, Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch